Chart Builder
Introduction
The EMDB Chart Builder (https://emdb-empiar.org/statistics/builder) is a web-based application that provides users with the ability to create customizable, dynamic, and informative charts that help analyse the holdings and trends of the EMDB and EMPIAR archives, powered by the EMDB search engine. The underlying data is based on the metadata of all EMDB entries, enriched by the EMICSS resource (https://emdb-empiar.org/emicss). This tool allows users to define specific search terms, enabling the extraction of data subsets that are directly relevant to their analysis objectives. By organising the extracted data into meaningful categories, users can generate insightful charts to visualise and analyse the results. The Chart Builder can be accessed at https://ebi.ac.uk/emdb/statistics/builder.This page presents a user-friendly interface specifically designed to facilitate the creation of customised charts using both EMDB and EMPIAR data.
Use of the Chart Builder requires some knowledge of the EMDB search engine. Therefore you might find it useful to read the search system documentation and the list of search fields. These resources provide valuable insights into the various search functionalities and parameters that can be employed to refine your data extraction.
The Chart builder now allows you to open and customise most of the charts available at /emdb/statistics. If you see an edit icon, simply click on it to open the corresponding chart in the Chart builder. This feature provides you with the flexibility to modify and personalise the chart according to your specific requirements, enabling you to derive deeper insights from the data visualisation.

Figure 1: Edit button available in EMstats plots.
Fields
Archive
Select if your chart is going to be using data about EMDB or EMPIAR. (Note: the amount of available metadata is currently much greater for EMDB than for EMPIAR.)
Chart type
The Chart Builder currently supports four types of charts:
- Line: This chart type is best suited for visualising trends and changes over time. It can be used to illustrate how properties of one or more subsets of entries evolve over time.
Figure 2: Line chart example
- Bar: The bar chart is ideal for comparing different categories or groups. It provides a visual representation of the distribution and relative magnitudes of specific entries within each category.
Figure 3: Bar chart example
- Pie: The pie chart is a useful tool for illustrating proportions and percentages. It provides a concise visual representation of the distribution of a selected subset of entries among various categories. Pie charts can only have one data series, and the data categories are defined by the Data X parameter.
Figure 4: Pie chart example
- Area: Similar to a line chart, the area chart emphasises the cumulative size of subsets of entries over time.
Figure 5: Area chart example
Global filter
The optional global filter in the Chart Builder allows you to specify a search term that will be applied to the selected entries for the entire chart. This feature ensures that the resulting plot focuses on the specific data subset defined by the search term. For instance, suppose you wish to create a plot showcasing the number of entries related to Sars-Cov-2 per EM method. In that case, you can simply change one of the previous examples and set the following query within the global filter: `natural_source_ncbi_code:"2697049"`. This query narrows down the data to entries associated with the Sars-Cov-2 NCBI code, enabling the creation of a customised plot that visualises the desired information accurately.
Figure 6: Area chart with global filter
Data X
The Data X field determines the data that will be displayed on the X-axis or as categories in a pie chart. Within this field, there are three types of data X definitions:
Year:
The X-axis values in the chart correspond to the release year of the entries. By modifying the Data X settings, you can refine the previously created SARS-CoV-2 chart to display data specifically from the year 2019 and beyond.
Figure 7: Area chart with global filter and zoomed from 2019 to 2023.
Experimental metadata:
When selecting the option of "Experimental metadata" for the Data X field, you have the ability to choose one of the enumeration categories. The chosen category's elements will be displayed on the X-axis of the chart. For instance, you can set the experimental metadata category as an EM method to showcase the number of Sars-Cov-2 entries per each type of experiment.
Figure 8: Column chart with global filter displaying categorical metadata on x-axis
Custom queries:
You can define custom queries to specify a set of criteria that will be displayed on the x-axis of the chart. This allows you to customise the chart further according to your specific requirements. For example, you can modify the previous chart to include only the columns related to single-particle, subtomogram averaging, and tomography by using custom queries.
Figure 9: Column chart with global filter displaying specific metadata on x-axis
Custom queries are particularly important when creating pie charts since they can only have a single data series, and the slices of the pie are defined by the elements in the custom queries. We can modify the previous chart to be displayed as a pie chart. This allows for a concise visual representation of the distribution of the selected subset of entries among each experiment method.
Figure 10: Pie chart with custom metadata on slices
Data Y:
The Data Y field is used to set what information is going to be displayed along the Y-axis of your chart. For example, you can choose to display the number of entries, publications, or resolution on the Y-axis, depending on the nature of your analysis and the insights you seek to derive from the chart.
Data series:
This field defines the data series that will be displayed in your chart. A data series consists of three pieces of information: operator, query, and label. The available operators depend on the selection made in the Data Y field. If Data Y is a numeric variable, the operator can be average, minimum, maximum, or sum. On the other hand, if Data Y is a categorical variable, the operator can be the count of unique values or cumulative values. Additionally, you can apply an optional filter query for each data series. This is useful when comparing multiple classes of information, as demonstrated in the example below.
Figure 11: Chart composed by multiple data series to illustrate the 10 most common virus families in EMDB
Attributes
There are seven attributes that can be used to print, download, export and change the chart visualisation:

- Change how area and columns are displayed. There are three options: unstacked, stacked and stacked percent.
- Select to display the data series in a logarithmic or linear scale.
- Share the current chart. The resulting URL will be copied into the clipboard.
- Print the current chart.
- Download the chart image or data table.
- Full Screen mode.
- Extra options.
Publications:
Quick links
Recent Entries
(Show all)Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 5, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 1, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 1, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 8
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 8
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1 and Olaparib, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 9
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 10
Nucleosome with an SSb at SHL +5.3 in complex with the WGR domain of PARP2, Class 2, consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 8
Structural Insights into HIV-1 Vif-Mediated Ubiquitination and Degradation of APOBEC3H
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 13
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 12
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of PARP2, Class 2
Human mitochondrial ClpP in complex with OICR-18704 in a partially-engaged tetradecameric state (intermediate opening)
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 1, Focused map
Human mitochondrial ClpP in complex with OICR-18704 in a partially-engaged tetradecameric state (minimal opening)
Human mitochondrial ClpP in complex with OICR-18704 in the heptameric state
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 2, Focused map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 1, Focus map
Human mitochondrial ClpP in complex with OICR-18704 in a partially-engaged tetradecameric state (maximal opening)
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 8, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 3, Focused map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 9, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 9, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 7, Focus map
Nucleosome with an SSD at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 9
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 4, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1 and Talazoparib, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 9, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 9, Focus
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 11, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 11, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 11
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 14, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 14, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 2, focus map
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 1, consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1 and Olaparib, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 14
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 1, focus map
Focused map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in precatalytic conformation
Cryo-EM structure of CRBN bound to 2-[5-chloro-1-(4-piperidyl)indol-4-yl]-2,5-diazaspiro[3.4]octan-6-one in the open conformation
Disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in recognition conformation
Disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in precatalytic conformation
Cryo-EM structure of CRBN bound to 1-[1-(4-piperidyl)indol-4-yl]hexahydropyrimidine-2,4-dione in the open conformation
Raw map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in recognition conformation
Raw map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in precatalytic conformation
Cryo-EM structure of CRBN bound to 1-[1-(4-piperidyl)indol-4-yl]hexahydropyrimidine-2,4-dione in the closed conformation
Focused map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in recognition conformation
Cryo-EM structure of monomeric bovine heart cytochrome c oxidase in amphipol A8-35
Cryo-EM structure of homotypic CENP-A nucleosome isolated from human cells
Structure of Human Aspartate--tRNA ligase 3-154 with linker and FC : ATYR0101
Cryo-EM structure of heterotypic CENP-A/H3 nucleosome isolated from human cells
A composite map of the mitochondrial ATP synthase monomer from Acanthamoeba castellanii
CryoEM structure of respiratory complex III intermediate from Acanthamoeba castellanii
Mitochondrial MDH and OSCP in the peripheral stalk of ATP synthase in Acanthamoeba castellanii
Membrane region of Acanthamoeba castellanii mitochondrial ATP synthase dimer
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 1, Myb domain focused)
Cryo-EM structure of STITCHR (R2Tg and Cas9 nickase) bound to guide RNA, template RNA, and target DNA in the target-primed reverse transcription initiation state
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 2)
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 3)
A Cryo-EM Map with a Continuous Density of Sld3-CTD Binding on Mcm4-NTD-A and Mcm6-NTD-A
A Local Refined Structure for Sld7 in Complex with Dbf4-bound Mcm6
Cdc45, Sld3 and Sld7 in Complex with DDK-bound MCM Double Hexamer
A Cryo-EM map for Sld3-Sld7 on Cdc45 and DDK-bound MCM Double Hexamer with a Highly Dynamic Sld3N and Sld7N
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 1)
CryoEM structure of DDB1-VprBP complex in "ARM-down" conformation
Immune complex comprising the HRSV preF trimer (SC-DM) and the monoclonal antibody Lor69 - Obtained by cryo-EM
Plasmodium falciparum 17-PF subpellicular microtubule associated with human hemoglobin (local refined map)
Plasmodium falciparum 17-PF subpellicular microtubule associated with human hemoglobin
Trans-1-azomorphine-3 bound mu opioid receptor Gi complex - Focused receptor map
Trans-2-azomorphine-3 bound mu opioid receptor Gi complex - Focused receptor map
Trans-2-azomorphine-3 bound mu opioid receptor Gi complex - Focused Gi map
cis-azomorphine-3 bound mu opioid receptor Gi complex - Focused Gi map
Cis-azomorphine-3 bound mu opioid receptor Gi complex - Focused receptor map
Trans-1-azomorphine-3 bound mu opioid receptor Gi complex - Focused Gi map
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 1
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 2
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 3
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 4
cAMP-bound SthK monomer from symmetry expanded particles - POPE class 2
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 8
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 6
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 7
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 5
cAMP-bound SthK monomer from symmetry expanded particles - POPE class 1
Cryo-EM structure of the flagellar filament in Vibrio parahaemolyticus VP288
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), bound to diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-7), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-4), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), state 2 (pre-translocation) after 5 min reaction
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), state 3 (post-translocation) after 5 min reaction
Candida albicans Chitin synthase 1 (CaChs1) bound to UDP-GlcNAc and diynyl arylamine (DA, aka RO-09-3143)
Human CI-M6PR/IGF2R (cation-independent mannose-6-phosphate receptor) cryo-EM structure low pH conformation
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-3), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1) in the apo state
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-5), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-6), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-2), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), state 1 (post UDP hydrolysis) after 5 min reaction
Drosophila MSLHAT nucleosome complex H4K16ac postcatalytic H3K36me3 reader state overall refinement
MSL HAT nucleosome complex active H4K16Ac state Overall refinement
Drosophila MSL HAT nucleosome complex H4K16ac postcatalytic H3K36me3 reader state focused refinement
Drosophila MSL HAT nucleosome complex H4K16ac post-catalytic state
Cryo-EM map of mouse PADI6-UHRF1-UBE2D2 complex (state 2), featuring a tetrameric assembly of PADI6
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the inverse agonist cmpd54-4, local
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the inverse agonist cmpd54-4
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the agonist dexamethasone phosphate (DEX-P),local
Cryo-EM structure of the MRGPRX4-miniGsq complex in the apo state
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the agonist dexamethasone phosphate (DEX-P)
Cryo-EM structure of the MRGPRX4-miniGsq complex in the apo state, local
Drosophila MSL HAT nucleosome complex H4K16ac postcatalytic H3K36me3 reader state
Cryo-EM structure of human TMEM45A with a bound 2-Hydroxypalmitate
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 10
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 9, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 10, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 8, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 10, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 9, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 5, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 7, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 8, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 9
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 5, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 4, Focus map
SARS-CoV-2 Omicron JD.1.1 spike trimer (S-6P) in complex with 3 R102-9 Fabs and 3 C092 Fabs, focused refinement of RBD and Fab region
SARS-CoV-2 Omicron JD.1.1 spike trimer (S-6P) in complex with 3 R102-9 Fabs and 3 C092 Fabs (3 RBD up)
Human condensin II bound to ADP-BeF3 in autoinhibited conformation
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled mouse brain biopsy frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled mouse brain biopsy frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled mouse brain biopsy frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
In-situ structure of the 80S yeast ribosome frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 5, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 5, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 8, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 4, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 7, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 5, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 4, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 6, Focus map
